STAAR Surgical Co
NASDAQ:STAA
Profitability Summary
STAAR Surgical Co's profitability score is 43/100. We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.
Score
We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.
We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.
Score
Score
Margins
Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.
Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Earnings Waterfall
STAAR Surgical Co
|
Revenue
|
279.1m
USD
|
|
Cost of Revenue
|
-72.6m
USD
|
|
Gross Profit
|
206.6m
USD
|
|
Operating Expenses
|
-251.6m
USD
|
|
Operating Income
|
-45.1m
USD
|
|
Other Expenses
|
-26m
USD
|
|
Net Income
|
-71.1m
USD
|
Margins Comparison
STAAR Surgical Co Competitors
| Country | Company | Market Cap |
Gross Margin |
Operating Margin |
Net Margin |
||
|---|---|---|---|---|---|---|---|
| US |
|
STAAR Surgical Co
NASDAQ:STAA
|
865.2m USD |
74%
|
-16%
|
-25%
|
|
| CH |
|
Alcon AG
SIX:ALC
|
35.8B CHF |
54%
|
14%
|
11%
|
|
| JP |
|
Hoya Corp
TSE:7741
|
5.9T JPY |
86%
|
29%
|
23%
|
|
| DK |
|
Coloplast A/S
CSE:COLO B
|
143B DKK |
68%
|
27%
|
16%
|
|
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
13.6B USD |
70%
|
16%
|
10%
|
|
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
5.9B GBP |
57%
|
15%
|
8%
|
|
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
50.3B CNY |
70%
|
43%
|
40%
|
|
| CH |
|
Ypsomed Holding AG
SIX:YPSN
|
5.6B CHF |
39%
|
15%
|
12%
|
|
| US |
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
5.6B USD |
64%
|
29%
|
17%
|
|
| US |
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
5.6B USD |
48%
|
12%
|
9%
|
|
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
7T KRW |
20%
|
-149%
|
-253%
|
Return on Capital
Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.
Return on Capital Comparison
STAAR Surgical Co Competitors
| Country | Company | Market Cap | ROE | ROA | ROCE | ROIC | ||
|---|---|---|---|---|---|---|---|---|
| US |
|
STAAR Surgical Co
NASDAQ:STAA
|
865.2m USD |
-19%
|
-15%
|
-11%
|
-22%
|
|
| CH |
|
Alcon AG
SIX:ALC
|
35.8B CHF |
5%
|
4%
|
5%
|
4%
|
|
| JP |
|
Hoya Corp
TSE:7741
|
5.9T JPY |
21%
|
17%
|
24%
|
32%
|
|
| DK |
|
Coloplast A/S
CSE:COLO B
|
143B DKK |
27%
|
9%
|
22%
|
11%
|
|
| US |
|
Align Technology Inc
NASDAQ:ALGN
|
13.6B USD |
11%
|
7%
|
16%
|
9%
|
|
| UK |
|
ConvaTec Group PLC
LSE:CTEC
|
5.9B GBP |
11%
|
5%
|
11%
|
9%
|
|
| CN |
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
50.3B CNY |
17%
|
16%
|
19%
|
24%
|
|
| CH |
|
Ypsomed Holding AG
SIX:YPSN
|
5.6B CHF |
13%
|
7%
|
15%
|
8%
|
|
| US |
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
5.6B USD |
24%
|
13%
|
26%
|
30%
|
|
| US |
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
5.6B USD |
9%
|
5%
|
7%
|
7%
|
|
| KR |
H
|
HLB Inc
KOSDAQ:028300
|
7T KRW |
-34%
|
-22%
|
-16%
|
-15%
|
Free Cash Flow
Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.
If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.
You don't have any saved screeners yet
